| Literature DB >> 23379631 |
Hortensia Moreno-Macías1, Douglas W Dockery, Joel Schwartz, Diane R Gold, Nan M Laird, Juan J Sienra-Monge, Blanca E Del Río-Navarro, Matiana Ramírez-Aguilar, Albino Barraza-Villarreal, Huiling Li, Stephanie J London, Isabelle Romieu.
Abstract
BACKGROUND: We previously reported that asthmatic children with GSTM1 null genotype may be more susceptible to the acute effect of ozone on the small airways and might benefit from antioxidant supplementation. This study aims to assess the acute effect of ozone on lung function (FEF(25-75)) in asthmatic children according to dietary intake of vitamin C and the number of putative risk alleles in three antioxidant genes: GSTM1, GSTP1 (rs1695), and NQO1 (rs1800566).Entities:
Mesh:
Substances:
Year: 2013 PMID: 23379631 PMCID: PMC3579760 DOI: 10.1186/1465-9921-14-14
Source DB: PubMed Journal: Respir Res ISSN: 1465-9921
Figure 1Study design. In the antioxidant study, asthmatic children were recruited from 1998 to 2000 and followed during 12 weeks with spirometric tests during the follow-up. At baseline, children were randomly assigned to either a placebo or a supplementation group (vitamin C 250 mg/day and vitamin E 50 mg/day). In the EVA study, asthmatic children were recruited and followed during 16 weeks from 2003 to 2004. Every two weeks children had a spirometric test. In both studies, children provided blood sample at baseline.
Characteristics of the study population of 257 asthmatic children residing in Mexico City 1998-2004
| Gender (%male) | 63.4 |
| Age (years) | 9.0 (7.2-11.0) |
| Height (cm) | 134 (123–145) |
| BMI | 18.5(16.1-21.6) |
| Antioxidant Study participants (%) | 56.0 |
| Supplementation group (%) | 30.4 |
| Vitamin C intake in supplementation group (mg/d) | 346 (329–375) |
| Vitamin C intake out of supplementation group (mg/d) | 105 (84–131) |
| Moderate- and severe-persistent asthma (%) | 39.3 |
| Mild-persistent asthma (%) | 24.5 |
| Mild-intermittent asthma (%) | 36.2 |
| Atopy (%)Ϫ | 83.7 |
| GSTM1 (Number of copies) † | |
| 0 | 93 (36.2) |
| 1 | 129 (50.2) |
| 2 | 35 (13.6) |
| Val/Val | 85 (33.1) |
| Ile/Val | 113 (44.0) |
| Ile/Ile | 59 (22.9) |
| Ile/Ile + Ile/Val | 172 (66.9) |
| NQO1 rs1800566 ‡ | |
| Pro/Pro | 67 (33.7) |
| Pro/Ser | 88 (44.2) |
| Ser/Ser | 44 (22.1) |
| Pro/Ser + Ser/Ser | 132 (66.3) |
| Mean (SD) | |
| Native-American | 70.9 (13.3) |
| European | 26.2 (12.4) |
| African | 2.9 (2.1) |
†n = 257; ‡n = 199; § n = 160.
*Median(Q25-Q75); Ϫ Defined by skin test.
Effect of ozone on FEF, according to genotype and vitamin C intake &
| | ||||||
|---|---|---|---|---|---|---|
| | ||||||
| GSTM1 | ||||||
| Null | 28 | −69.0 (−144.0, 6.0)£ | 34 | −16.2 (−66.8, 34.4) | 31 | −13.8 (−58.5, 30.9) |
| Positive | 57 | −12.6 (−57.3, 32.1) | 60 | 22.2 (−23.7, 68.1) | 47 | 6.9 (−38.9, 52.8) |
| Genotype effect Ω | | 56.4 (−138.0, 27.0) | | 38.4 (−31.2,108.0) | | 20.7 (−43.2, 84.6) * |
| Null | 17 | −91.2 (−184.1, 1.7)£ | 24 | −23.4 (−81.0, 34.2) | 24 | −13.2 (−77.9, 51.5) |
| Positive | 28 | −35.4 (−102.4, 31.6) | 36 | −15.6 (−69.7, 38.4) | 35 | 13.8 (−40.3, 67.9) ** |
| Genotype effect | | 55.8 (56.4, -168.0) | | 7.8 (−114.0, 84.0) | | 27.0 (−57.6, 111.6) |
| GSTP1 rs1695 | ||||||
| Val/Val | 27 | −43.2 (−106.7, 20.3) | 31 | 2.4 (−56.4, 61.2) | 27 | 3.6 (−65.8, 73.0) |
| Ile/Val + Ile/Ile | 58 | −24.0 (−74.6, 26.6) | 63 | 7.8 (−32.2, 47.8) | 51 | 3.6 (−35.2, 42.4) |
| Genotype effect | | 19.2 (−68.4, 106.8) | | 5.4 (−65.4, 76.2) | | 0.0 (−79.8, 79.8) |
| Val/Val | 13 | −82.8 (−167.5, 1.9)£ | 21 | −33.0 (−104.7, 38.7) | 20 | 18.2 (−67.8, 103.8) * |
| Ile/Val + Ile/Ile | 32 | −54.0 (−119.9, 11.9) | 39 | −12.0 (−59.0, 35.0) | 39 | 0.0 (−49.4, 49.4) |
| Genotype effect | | 28.8 (−96.6, 154.2) | | 21.0 (−64.8, 106.8) | | −18.2 (−117.0, 81.0) |
| NQO1 rs1800566* | ||||||
| Pro/Pro | 24 | −55.2 (−134.0, 23.6) | 22 | 50.4 (−17.8, 118.6) | 21 | −37.8 (−114.2, 38.6) |
| Pro/Ser + Ser/Ser | 36 | −4.8 (−62.4, 52.8) | 42 | −10.8 (−56.7, 35.1) | 54 | 10.8 (−29.2, 50.8) |
| Genotype effect | | 50.4 (−45.4, -144.0) | | −61.2(−141.6, 192.0) | | 48.6 (−31.2,126.0) |
| Pro/Pro | 14 | −75.0 (−182.0, 32.0) | 13 | −0.3 (−69.7, 69.1) | 19 | −39.6 (−119.6, 40.4) |
| Pro/Ser + Ser/Ser | 23 | −42.0 (−105.5, 21.5) | 31 | −17.4 (−70.3, 35.5) | 37 | 17.4 (−32.0, 69.0) ** |
| Genotype effect | 33.0 (−84.0,150.0) | −17.1(−111.6, 77.4) | 57.0(−32.8,146.4) | |||
Models were adjusted for gender, age, BMI, height, time, cohort, use of bronchodilator, and minimum temperature. All asthmatics: n = 257 and 4548 repeated measures; persistent (mild, moderate, or severe) asthmatics: n = 164 and 3029 repeated measures.
*NQO1 models: all asthmatics n = 199 and 3842 repeated measures; persistent (mild, moderate, or severe): n = 137 and 2715 repeated measures. € p ≤ 0.05; £ 0.05 < p < 0.1; Ω Genotype effect is defined to be the change in response produced by a change in the level of genotype.
*p-trend ≤ 0.05; ** 0.05 < p-trend < 0.1.
&FEF25-75 is reported as ml/s per 1-h 60 ppb on the day prior to spirometric test.
Figure 2Effect of ozone on FEF and 95% CI according to genotypes and vitamin C intake. Persistently asthmatic children with vitamin C intake between 30 to 105 mg/day and with GSTM1 null had lower levels of FEF25-75 than children with either GSTM1 positive genotype or dietary vitamin C intake higher than 105 mg/day. Similar situation was observed for Val/Val vs. Ile/Val + Ile/Ile GSTP1 polymorphisms. Linear mixed models were adjusted for age, gender, BMI, height, cohort, time, use of bronchodilator, and previous day’s minimum temperature. Reported values correspond to the effect on FEF25-75 per 60 ppb of ozone.
Effect of ozone on FEF, according to the number of risk alleles and vitamin C &
| | | ||||
|---|---|---|---|---|---|
| 1 to 3 | 30 | 24.0 (−50.0, 98.1) | 73 | 27.0 (−16.5, 70.5) | 3.0 (−82.2, 88.2) |
| 4 to 6 | 30 | −58.8 (−122.3, 0.1) £ | 66 | −16.8 (−49.7, 16.1) | 42.0(−24.0, 108.0) |
| Genotype effect Ω | | −82.8 (−180.0, 15.0) £ | | −43.8 (−98.4, 11.4) | |
| 1 to 3 | 18 | 19.2 (−67.8, 106.2) | 50 | 15.6 (−35.0, 66.2) | −3.6 (−105.6, 98.4) |
| 4 to 6 | 19 | − | 50 | −18.6 (−58.6, 21.4) | 78.6 (77.1, 80.1) £ |
| Genotype effect | −116.4 (−118.4, -114.4) £ | −34.2 (−98.4, 30.0) | |||
Models were adjusted for gender, age, BMI, height, chronological time, cohort, use of bronchodilator, and minimum temperature. All asthmatics: n = 199 and 3842 repeated measures; persistent (mild, moderate or severe) asthmatics: n = 137 and 2715 repeated measures.
€ p ≤ 0.05; £ 0.05 < p ≤ 0.1; Ω Genotype effect is defined to be the change in response produced by a change in the level of genotype.
Π Diet effect is defined to be the change in response produced by a change in the level of diet intake. &FEF25-75 is reported as ml/s per 1-h 60 ppb on the day prior to spirometric test.
Figure 3Effect of ozone on FEF and 95% CI according to genotype score and vitamin C intake. Persistently asthmatic children with vitamin C intake between 30 to 105 mg/day (low diet) and with 4 to 6 risk alleles had lower levels of FEF25-75 than children with either 1 to 3 risk alleles or dietary vitamin C intake higher than 105 mg/day (high diet). Linear mixed models were adjusted for age, gender, BMI, height, cohort, time, use of bronchodilator, and previous day’s minimum temperature. N = 137 asthmatic children and 2715 repeated measures.